Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis.

Clin Kidney J · 2025 · PMC12686814 · PMID 41377851

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Moreover, during the initial period of primary Fabry therapy, proteinuria exhibited a slight, borderline significant, worsening trend.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.